TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33939006
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants in both groups
Study: 33939067
Drug: DSP-7888 administered
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSP-7888 administered intradermally (ID) at doses of 3.5 mg, 10.5 mg, and 17.5 mg.
Study: 33939067
Drug: DSP-7888 administered
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DSP-7888 administered subcutaneously (SC) at doses of 3.5 mg and 10.5 mg.
Study: 33939068
Drug: Savolitinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib monotherapy 400 mg once daily (qd)
Study: 33939068
Drug: Savolitinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib monotherapy 600 mg qd
Study: 33939068
Drug: Savolitinib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 400 mg qd + Osimertinib 80 mg
Study: 33939068
Drug: Savolitinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 300 mg qd + Osimertinib 80 mg
Study: 33939068
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg qd + Osimertinib 80 mg
Study: 33940581
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl (250 or 500 mg thrice daily)
Study: 37486343
Drug: Rucaparib (PARP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (PARP inhibitor)
Study: 33941878
Drug: WNT974 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: WNT974 (10 mg once-daily)
Study: 33942031
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of biological therapy
Study: 33942031
Drug: Treatment changes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment changes due to the pandemic
Study: 33942128
Drug: Ponatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib treatment
Study: 33942298
Drug: Novel MYC-non-IG
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel MYC-non-IG fusion treatment
Study: 33942621
Drug: Standardized diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized diluted diesel exhaust (300 µg/m³)
Study: 33942745
Drug: Cricothyroid method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cricothyroid method for lignocaine administration
Study: 33942745
Drug: Spray-as-you-go method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-as-you-go method for lignocaine administration
Study: 33942954
Drug: Cemiplimab plus
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab plus radiation therapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor (GM-CSF)
Study: 33944810
Drug: Early Physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Physical Therapy after Multiligament Surgery
Study: 33944977
Drug: Cranial microwave
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial microwave scanner in conjunction with nine brain biomarkers (Aβ40, Aβ42, GFAP, H-FABP, S100B, NF-L, NSE, UCH-L1 and IL-10)
Study: 33945049
Drug: RC48 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 (2.5 mg/kg Q2W)
Study: 33945291
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without focal proton or photon radiation therapy (RT)
Study: 37978197
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus high-dose trastuzumab (6 mg/kg weekly)
Study: 33945297
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg once daily until disease progression or treatment intolerance
Study: 33945497
Drug: Wearable sensors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable sensors (Fitbit Charge 3 smartwatch and TempTraq temperature patches) and smartphone-based symptom logging for 30 days.
Study: 33945497
Drug: Daily mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mood score logging and symptom reporting via smartphone app (Roadmap 2.0) for 30 days.
Study: 33945596
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) with 2.4 ml SonoVue intravenous bolus
Study: 33945605
Drug: Whole-blood standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-blood standard flow cytometric assay to identify pathogenic antibodies associated with VITT
Study: 33947696
Drug: Palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib + fixed-dose vemurafenib
Study: 33947745
Drug: Mediator of
Normalized name: Mediator of inflammation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediator of DNA Damage Checkpoint 1 (MDC1) as an estrogen receptor coregulator
Study: 33948123
Drug: Upfront brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront brain radiotherapy (BR) with chemotherapy (platin-pemetrexed and bevacizumab), followed by maintenance pemetrexed with or without bevacizumab.
Study: 33948123
Drug: Chemotherapy (ChT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ChT) with brain radiotherapy (BR) only at cerebral progression.
Study: 33948447
Drug: ACLR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLR treatment
Study: 33948447
Drug: Non-ACLR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACLR treatment
Study: 33948606
Drug: DSM-XC (two-factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM-XC (two-factor solution by Lace & Merz, 2020)
Study: 33948606
Drug: DSM-XC (six-factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM-XC (six-factor solution)
Study: 33948606
Drug: DSM-XC (bifactor
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM-XC (bifactor solution)
Study: 33949004
Drug: Screw-retained one-piece
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screw-retained one-piece implant crowns fabricated with zirconia abutments
Study: 33949080
Drug: Implant removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant removal due to peri-implantitis with simultaneous bone regeneration procedures and the use of a removal kit
Study: 33949080
Drug: Implant removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant removal due to peri-implantitis
Study: 33949959
Drug: Tailored Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Internet-delivered cognitive behavioral therapy (ICBT)
Study: 33952345
Drug: 1-week compressed
Normalized name: ULVA COMPRESSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week compressed course of left dorsolateral prefrontal (L DLPFC) 5 Hz accelerated rTMS (aTMS)
Study: 33952345
Drug: 5 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Hz L DLPFC aTMS treatments for non-responders
Study: 33952559
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose ibuprofen (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals)
Study: 33952559
Drug: Adjustable dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dose ibuprofen (10 mg/kg followed by two doses of 5 mg/kg at 24 hours intervals if treated within the first 7 days after birth; higher doses up to 20 mg/kg followed by two doses of 10 mg/kg at 24 hours intervals if treated after the postnatal age cut-off)
Study: 33952559
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg every 6 hours for 3-7 days)
Study: 33952559
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin (0.1-0.3 mg/kg intravenous every 12-24 hours for a total of three doses)
Study: 33953626
Drug: Transvenous phrenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous phrenic nerve stimulation (TPNS) therapy
Study: 33953800
Drug: No atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atorvastatin
Study: 33954265
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose dolutegravir
Study: 33954265
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose dolutegravir
Study: 33954826
Drug: Clearing solution
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL LIQUID [Kiehls Since 1851 Dermatologist Solutions Truly Targeted Acne Clearing Solution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearing solution
Study: 33955240
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin 16.5% (cutaquig)
Study: 33955376
Drug: 5-cytokine panel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-cytokine panel (Angiopoietin 2, hepatocyte growth factor, interleukin 8, resistin, soluble tumor necrosis factor receptor 1A)
Study: 33955798
Drug: Serum anti-pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti-pertussis toxin (PT) antibodies measured using an enzyme-linked immunosorbent assay at 12 months (M12) and 24 months (M24) after enrollment.
Study: 33955818
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy intervention, details not available
Study: 33956223
Drug: Interventions targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions targeting regularity of daily routines
Study: 33956667
Drug: Pfizer/BioNTech vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer/BioNTech vaccine (1 dose)
Study: 33956667
Drug: Pfizer/BioNTech vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer/BioNTech vaccine (2 doses)
Study: 33956775
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise with enhanced therapeutic alliance (e.g., active listening, personalized conversation, empathy)
Study: 33956775
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise with limited therapeutic alliance (e.g., one-way verbalization, brief interaction)
Study: 33957901
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg daily with copper gluconate (8 mg of elemental copper)
Study: 33957901
Drug: Disulfiram 250
Normalized name: disulfiram 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 250 mg daily with copper gluconate (2, 4, 6 mg of elemental copper)
Study: 33959007
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance treatment, dosage and duration not specified
Study: 33959044
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral therapy (CBT) for depression
Study: 33959925
Drug: Drug-Shock (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Shock (IV procainamide followed by electrical cardioversion)
Study: 33959925
Drug: Shock-Only (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock-Only (placebo infusion followed by electrical cardioversion)
Study: 33959925
Drug: Drug-Shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Shock
Study: 33960949
Drug: haMSter mobile
Normalized name: hamster skin extract
DrugBank: Mesocricetus auratus skin (DB10605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: haMSter mobile health solution for remote monitoring of patient-reported outcomes (PROs)
Study: 33962566
Drug: Almonertinib for
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonertinib for 2 months followed by concurrent radiotherapy (induction group, arm A)
Study: 33962566
Drug: Concurrent almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent almonertinib with thoracic radiotherapy (concurrent group, arm B)
Study: 33963084
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management device for adherence to hydroxychloroquine
Study: 33963573
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily for seven consecutive days
Study: 33963740
Drug: 2hPG ≥8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2hPG ≥8.5 mmol/L
Study: 33964664
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (1004 participants)
Study: 33964664
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin use (1494 participants)
Study: 33964917
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Order (CTO) status
Study: 33965000
Drug: Lumacaftor-ivacaftor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor-ivacaftor (100 mg-125 mg every 12 h for <14 kg, 150 mg-188 mg for ≥14 kg, 200 mg-250 mg for ≥6 years)
Study: 33965006
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment scale-up (12 weeks of sofosbuvir plus velpatasvir)
Study: 33965006
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment scale-up
Study: 33965236
Drug: GCSF (Neupogen)
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF (Neupogen) at 5 μg/kg
Study: 33965236
Drug: GCSF (Neupogen)
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF (Neupogen) at 10 μg/kg
Study: 33966087
Drug: Single-agent ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent ibrutinib
Study: 33966087
Drug: Ibrutinib in
Normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib in combination with methotrexate with or without rituximab
Study: 38554570
Drug: Intravesical Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Bacillus Calmette-Guérin (BCG) combined with intravenous pembrolizumab
Study: 33966491
Drug: Andexanet alfa
Normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Andexanet alfa (bolus plus 2-hour infusion)
Study: 33966493
Drug: Capsaicin doses
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin doses (33 to 165 μMol)
Study: 33966568
Drug: Opioid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid infusion with rapid once-daily weaning, especially rate reduction more than 50 µg as fentanyl equivalent per hour
Study: 33966568
Drug: Opioid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid infusion with rapid once-daily weaning
Study: 33966568
Drug: Opioid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid infusion
Study: 33966635
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CMR and hemodynamic measurements
Study: 33967195
Drug: Bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles (and up to eight cycles).
Study: 33968064
Drug: Late antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late antiretroviral therapy (ART)
Study: 33970392
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HER2 and ER biomarkers, %HbT at the end of cycle 1 (EOC1), and %US (EOC1)
Study: 33970864
Drug: Cardiorespiratory exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiorespiratory exercise plus Chinese herbal medicines
Study: 33970864
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines only
Study: 33970864
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list group (receiving Chinese herbal medicines after 24 weeks)
Study: 33971009
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (Boostrix; GSK) during pregnancy
Study: 39058315
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously every 4 weeks
Study: 33971856
Drug: mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab 100 mg administered subcutaneously
Study: 33972949
Drug: Lenzilumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenzilumab (600 mg, n=261)
Study: 33972949
Drug: Lenzilumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenzilumab (600 mg)
Study: 33973293
Drug: Subcutaneous envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous envafolimab 0.01-10 mg/kg once weekly
Study: 33973293
Drug: Subcutaneous envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous envafolimab 300 mg once every 4 weeks
Study: 33974038
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (GT) using autologous bone marrow CD34+ cells transduced with MND-ADA gammaretroviral vector, infused after busulfan reduced-intensity conditioning.
Study: 33975557
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin D status (25(OH) D < 50 nmol/L) in rectal cancer patients
Study: 33976538
Drug: Camrelizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (3 mg/kg) combined with FOLFOX4 every two weeks
Study: 33978600
Drug: TNF-blockers
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-blockers
Study: 33978600
Drug: JAK-inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK-inhibitors
Study: 33978600
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment after achieving remission
Study: 33979178
Drug: Lifileucel (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifileucel (autologous tumor-infiltrating lymphocyte therapy) with a nonmyeloablative lymphodepletion regimen and up to six doses of high-dose interleukin-2.
Study: 33979178
Drug: Lifileucel in
Normalized name: lifileucel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifileucel in primary refractory to anti-PD-1 or PD-L1 therapy subset.
Study: 33979653
Drug: Passive-Scattering Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive-Scattering Proton Therapy (PSPT)
Study: 33980232
Drug: Moderate sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate sedation with oral administration of ketamine and midazolam
Study: 33980575
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose per fraction radiation
Study: 33981160
Drug: Initial epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Study: 33981160
Drug: Repeat epidural
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Study: 33981160
Drug: Initial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial and repeat SP-102 injections
Study: 33982128
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentration ≤9.9 ng/mL
Study: 33982128
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D concentration >9.9 ng/mL
Study: 33982376
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg, multiple oral doses on days 1-4)
Study: 33982376
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg, multiple oral doses on days 11-17)
Study: 33982376
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Vancomycin (1000 mg metformin on days 16-19)
Study: 33983492
Drug: Pre-treatment tumour-associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment tumour-associated lymphocytes (TILs)
Study: 33983492
Drug: Neo-adjuvant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant treatment
Study: 33984539
Drug: Daily ambulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ambulatory activity (AA) monitoring using accelerometric data from an insertable cardiac monitor.
Study: 36627145
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg intravenously every 3 weeks
Study: 33984675
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy (IT) with cytarabine or thiotepa
Study: 33984675
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy (IT) with methotrexate